1 / 10

Asia Pacific Radiopharmaceuticals Market to Reach $2.9 Billion By 2024

Asia Pacific Radiopharmaceuticals Market Analysis By Product (Diagnostics: SPECT, PET; Therapeutics: Alpha Emitters, Beta Emitters, Brachytherapy), By Type (Catheter, Doppler OCT, Handheld, Tabletop), By Application (Diagnostics: Cardiology, Neurology, Oncology, Thyroid, Lymphoma; Therapeutics: Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumor) And Segment Forecasts to 2024

Marsh
Download Presentation

Asia Pacific Radiopharmaceuticals Market to Reach $2.9 Billion By 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Asia Pacific Radiopharmaceuticals Market Analysis, Size, Growth, Share & Forecast to 2024 | Grand View Research Inc. “Asia Pacific Radiopharmaceuticals Market to Reach $2.9 Billion By 2024” The APAC Radiopharmaceuticals/Nuclear Medicine Market is expected to reach USD 2.9 billion by 2024, according to the new report by Grand View Research, Inc. Radiopharmaceuticals are widely used in the field of oncology, and cardiovascular diseases. Ongoing research and studies demonstrating positive results is widening the scope of radioisotope applications for the diagnosis and treatment of bone diseases, respiratory diseases, thyroid-related diseases, and conditions of the digestive tract. Along with these applications, the radioisotopes are largely used in radiopharmacology to study drug movement in lab subjects. Gamma emitter Technetium-99m is the most commonly used radioisotope in radiopharmaceuticals. Other widely used radioisotopes include Fluorine-18, Indium-111, and Iodine-131. Numerous research studies are further expanding the application areas of radiopharmaceuticals in diagnostics as well as in therapeutics. Adoption of PET as a diagnostic tool is rapidly increasing since it offers high accuracy over other diagnostic techniques. The accuracy in the diagnosis has a direct impact on decision-making and treatment monitoring process. PET is commonly integrated with X-ray and computed tomography to increase the accuracy. The growing demand for these diagnostic procedures is expected to fuel the market growth during the forecast period. Currently available cancer treatment options, such as chemotherapy and radiation therapy, include drugs and radiations, which are non-target specific. Thus, these therapies have a major disadvantage of affecting the whole body or the organs surrounding the target site. Radioisotopes have an advantage over these techniques since they aid in targeting specifically the tumor without affecting the surrounding body parts. Thus, benefits associated with these diagnostic and treatment procedures is augmenting the demand for radiopharmaceuticals in disease treatment and diagnosis. Follow Us:

  2. Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/asia-pacific- radiopharmaceuticals-market Further key findings from the study suggest: The buyers of radiopharmaceutical include hospitals, physicians, diagnostic laboratories, research institutes and others. Hospitals form the biggest buyer groups owing to their high patient turnover and greater financing capabilities. • Therapeutic products such as Alpha Emitters, Beta Emitters and Brachytherapy are anticipated to exhibit lucrative growth. Emergence of new treatment options for thyroid and other diseases is expected to support the growth over the forecast period. • The key diagnostic application areas of radiopharmaceuticals formed the largest market in 2015. These applications are in cardiology, neurology, oncology, and thyroid. Advent of accurate diagnostic methods and high burden of disorders supported the growth of this segment. • Thailand in South East Asia and China are expected to dominate the APAC radiopharmaceutical market. Efforts undertaken by the UN and other local healthcare authorities in this region are expected to result in installation of more PET and SPECT systems, thereby driving the demand. • Key players of the industry include Nordion, Inc., Bayer AG, Mallinckrodt Public Limited company, GE Healthcare, Bracco Imaging S.P.A and government initiatives such as Institute of Radioisotopes and The Australian Nuclear Science and Technology Organization (ANSTO) • Grand View Research has segmented the APAC radiopharmaceuticals market on the basis of product: APAC Radiopharmaceuticals Product Outlook (Revenue, USD Million, 2013 - 2024) Diagnostics • oSPECT oTC-99m oTL-201 oGA-67 oI-123 oOthers oPET oF-18 oRB-82 oOthers Follow Us:

  3. Therapeutics • oAlpha Emitters oRA-223 oBeta Emitters oI-131 oY-90 oSM-153 oRe-186 oLu-117 oOthers oBrachytherapy oCesium-131 oIodine-125 oPalladium-103 oIridium-192 oOthers Radiopharmaceuticals Regional Outlook (Revenue, USD Million, 2013 - 2024) South East Asia • oIndonesia oThailand oLaos oMyanmar oPhilippines oMalaysia oVietnam oCambodia Follow Us:

  4. Rest of Asia Pacific • oJapan oChina oIndia Table of Content Chapter 1 Research Methodology 1.1 Information procurement 1.2 Data Analysis Chapter 2 Executive Summary Chapter 3 Market Snapshot Chapter 4 Market Variables, Trends & Scope 4.1 Market segmentation & scope 4.1.1 Market Driver Analysis 4.1.1.1 Rising incidence of cancer and cardiovascular disease 4.1.1.2 Widening applications of radiopharmaceuticals 4.1.1.3 Growing demand for the accurate diagnostic methods 4.1.2 Market Restraint Analysis 4.1.2.1 Stringent regulation for production, storage, and usage 4.1.2.2 High costs involved in the procedure 4.2 Radiopharmecuticals - PESTLE Analysis 4.3 Industry Analysis - Porter’s 4.4 Penetration Index 4.5 Radiopharmaceuticals: Buyer profile 4.6 List of suppliers 4.7 Average Selling Price Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis 5.1 Radiopharmaceuticals market: Product movement analysis 5.2 Diagnostic products 5.2.1 Diagnostic products market, 2013 - 2024 (USD Million) 5.2.2 SPECT 5.2.2.1 SPECT products market, 2013 - 2024 (USD Million) Follow Us:

  5. 5.2.3 TC-99m 5.2.3.1 TC-99m market, 2013 - 2024 (USD Million) 5.2.3.2 TL-201 5.2.3.3 TL-201 market, 2013 - 2024 (USD Million) 5.2.3.4 GA-67 5.2.3.5 GA-67 market, 2013 - 2024 (USD Million) 5.2.3.6 I-123 5.2.3.6.1 I-123 market, 2013 - 2024 (USD Million) 5.2.3.7 Other SPECT products 5.2.3.8 Other SPECT products market, 2013 - 2024 (USD Million) 5.2.4 PET 5.2.4.1 PET products market, 2013 - 2024 (USD Million) 5.2.4.2 F-18 5.2.4.2.1 F-18 market, 2013 - 2024 (USD Million) 5.2.4.3 RB-82 5.2.4.4 RB-82 market, 2013 - 2024 (USD Million) 5.2.4.5 Other PET products 5.2.4.5.1 Other PET products market, 2013 - 2024 (USD Million) 5.3 Therapeutic products 5.3.1 Therapeutic products market, 2013 - 2024 (USD Million) 5.3.2 Alpha emitters 5.3.2.1 Alpha emitters market, 2013 - 2024 (USD Million) 5.3.2.2 RA-223 5.3.2.2.1 RA-223 market, 2013 - 2024 (USD Million) 5.3.2.3 Other alpha emitters 5.3.2.3.1 Other alpha emitters market, 2013 - 2024 (USD Million) 5.3.3 Beta emitters 5.3.3.1 Beta emitters market, 2013 - 2024 (USD Million) 5.3.3.2 I-131 5.3.3.2.1 I-131 market, 2013 - 2024 (USD Million) 5.3.3.3 Y-90 5.3.3.3.1 Y-90 market, 2013 - 2024 (USD Million) 5.3.3.4 SM-153 5.3.3.4.1 SM-153 market, 2013 - 2024 (USD Million) Follow Us:

  6. 5.3.3.5 Re-186 5.3.3.5.1 Re-186 market, 2013 - 2024 (USD Million) 5.3.3.6 Lu-117 5.3.3.6.1 Lu-117 market, 2013 - 2024 (USD Million) 5.3.3.7 Other beta emitters 5.3.3.7.1 Other beta emitters market, 2013 - 2024 (USD Million) 5.3.4 Brachytherapy 5.3.4.1 Brachytherapy market, 2013 - 2024 (USD Million) 5.3.4.2 Cesium-131 5.3.4.2.1 Cesium-131 market, 2013 - 2024 (USD Million) 5.3.4.3 Iodine-125 5.3.4.3.1 Iodine-125 market, 2013 - 2024 (USD Million) 5.3.4.4 Palladium-103 5.3.4.4.1 Palladium-103 market, 2013 - 2024 (USD Million) 5.3.4.5 Iridium-192 5.3.4.6 Iridium-192 market, 2013 - 2024 (USD Million) 5.3.4.7 Other brachytherapy products 5.3.4.7.1 Other brachytherapy products market, 2013 - 2024 (USD Million) Chapter 6 Market Categorization 2: Application Estimates & Trend Analysis 6.1 Radiopharmaceuticals market: Application movement analysis 6.2 Diagnostic application 6.2.1 Diagnostic application market, 2013 - 2024 (USD Million) 6.2.2 Cardiology 6.2.2.1 Cardiology applications market, 2013 - 2024 (USD Million) 6.2.3 Neurology 6.2.3.1 Neurology applications market, 2013 - 2024 (USD Million) 6.2.4 Oncology 6.2.4.1 Oncology applications market, 2013 - 2024 (USD Million) 6.2.5 Thyroid 6.2.5.1 Thyroid applications market, 2013 - 2024 (USD Million) 6.2.6 Lymphoma 6.2.6.1 Lymphoma applications market, 2013 - 2024 (USD Million) 6.2.7 Other diagnostic application 6.2.7.1 Other diagnostic applications market, 2013 - 2024 (USD Million) Follow Us:

  7. 6.3 Therapeutic application 6.3.1. Therapeutic application market, 2013 - 2024 (USD Million) 6.3.2 Thyroid 6.3.2.1 Thyroid applications market, 2013 - 2024 (USD Million) 6.3.3 Bone metastasis 6.3.4 Bone metastasis applications market, 2013 - 2024 (USD Million) 6.3.5 Lymphoma 6.3.5.1 Lymphoma applications market, 2013 - 2024 (USD Million) 6.3.6 Endocrine tumor 6.3.6.1 Endocrine tumor market, 2013 - 2024 (USD Million) 6.3.7 Other therapeutic application 6.3.7.1 Other therapeutic applications market, 2013 - 2024 (USD Million) Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Product and Applications 7.1 Asia Pacific Radiopharmaceuticals market share by region, 2015 & 2024 7.2 Southeast Asia 7.2.1 Southeast Asia radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.2 Indonesia 7.2.2.1 Indonesia radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.3 Thailand 7.2.3.1 Thailand radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.4 Laos 7.2.4.1 Laos radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.5 Myanmar 7.2.5.1 Myanmar radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.6 Philippines 7.2.6.1 Philippines radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.7 Malaysia 7.2.7.1 Malaysia radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.8 Vietnam 7.2.8.1 Vietnam radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.2.9 Cambodia 7.2.9.1 Cambodia radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.3 Rest of Asia Pacific 7.3.1 Rest of Asia Pacific radiopharmaceuticals market, 2013 - 2024 (USD Million) Follow Us:

  8. 7.3.2 Japan 7.3.2.1 Japan radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.3.3 China 7.3.3.1 China radiopharmaceuticals market, 2013 - 2024 (USD Million) 7.3.4 India 7.3.4.1 India radiopharmaceuticals market, 2013 - 2024 (USD Million) Chapter 8 Competitive Landscape 8.1 Bayer AG 8.1.1 Company Overview 8.1.2 Financial Performance 8.1.3 Product Benchmarking 8.1.4 Strategic Initiatives 8.2 Mallinckrodt public limited company 8.2.1 Company Overview 8.2.2 Financial Performance 8.2.3 Product Benchmarking 8.2.4 Strategic Initiatives 8.3 GE Healthcare 8.3.1 Company Overview 8.3.2 Financial Performance 8.3.3 Product Benchmarking 8.3.4 Strategic Initiatives 8.4 Jubilant Life Sciences 8.4.1 Company Overview 8.4.2 Financial Performance 8.4.3 Product Benchmarking 8.4.4 Strategic Initiatives 8.5 Bracco Imaging S.p.A 8.5.1 Company Overview 8.5.2 Financial Performance 8.5.3 Product Benchmarking 8.5.4 Strategic Initiatives 8.6 Nordion, Inc. 8.6.1 Company Overview Follow Us:

  9. 8.6.2 Financial Performance 8.6.3 Product Benchmarking 8.6.4 Strategic Initiatives 8.7 The Institute for Radioelements (The IRE) 8.7.1 Company Overview 8.7.2 Financial Performance 8.7.3 Product Benchmarking 8.7.4 Strategic Initiatives 8.8 Australian Nuclear Science & Technology Organization (ANSTO) 8.8.1 Company Overview 8.8.2 Financial Performance 8.8.3 Product Benchmarking 8.9 NTP Radioisotopes SOC Ltd. 8.9.1 Company Overview 8.9.2 Financial Performance 8.9.3 Product Benchmarking 8.9.4 Strategic Initiatives 8.10 Eczacibasi-Monrol 8.10.1 Company Overview 8.10.2 Financial Performance 8.10.3 Product Benchmarking 8.10.4 Strategic Initiatives Follow Us:

  10. About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email:sales@grandviewresearch.com For More Information:https://www.grandviewresearch.com Follow Us:

More Related